AptaBio Therapeutics Inc.
Financials
Valuation Metrics
AptaBio Therapeutics Inc.'s Market Cap is ₩1472B. At end of 2025 it was ₩2627B. Ranked #983 of 2,410 in KR market (top 41%), #482 of 1,631 on KOSDAQ (top 30%), #116 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 147.21B KRW | KR#983/2,410 Sec#116/231 |
| Revenue | 4.75B KRW | KR#2,335/2,410 Sec#198/231 |
| Net Income | -14.87B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 54.40B KRW | KR#2,164/2,410 Sec#193/231 |
| Net Assets | 42.20B KRW | KR#2,013/2,410 Sec#175/231 |
| Employees | 34 | KR#2,168/2,410 Sec#201/231 |
| Value | ||
| P/B | 3.49x | KR#2,179/2,410 Sec#182/231 |
| P/S | 30.97x | KR#2,352/2,410 Sec#193/231 |
| Profitability | ||
| ROE | -35.23% | KR#2,213/2,410 Sec#187/231 |
| ROA | -27.34% | KR#2,291/2,410 Sec#195/231 |
| Op. Margin | -394.38% | KR#2,346/2,410 Sec#199/231 |
| Revenue Growth | 52.91% | KR#190/2,410 Sec#25/231 |
| Financial Health | ||
| Debt Ratio | 28.90% | KR#555/2,410 Sec#63/231 |
| Total Debt | 11.98B KRW | KR#1,561/2,410 Sec#138/231 |
| Cash | 14.71B KRW | KR#1,444/2,410 Sec#116/231 |
| Current Ratio | 2.54x | KR#672/2,410 Sec#85/231 |
| Performance | ||
| 1Y Return | -25.25% | KR#1,378/2,410 Sec#103/231 |
| 1M Return | -32.82% | KR#2,226/2,410 Sec#219/231 |
| From 52W High | -51.88% | KR#1,317/2,410 Sec#104/231 |
| 1Y MDD | -61.61% | KR#1,533/2,410 Sec#123/231 |
| Trading | ||
| Volume | 30,090 shares | KR#966/2,410 Sec#97/231 |
| Trading Value | 155.8M KRW | KR#1,038/2,410 Sec#116/231 |
| Foreign Own. | 1.45% | KR#1,837/2,410 Sec#181/231 |
| Per Share | ||
| EPS | -529 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,502 KRW | KR#2,200/2,410 Sec#191/231 |
Company Info
Aptabio, established in 2009 and specially listed on KOSDAQ in 2019, is a new drug development company based on platform technology, headquartered in Yongin-si, Gyeonggi-do. The company develops innovative new drugs, including for diabetes complications and as immune-oncology agents, utilizing three platform technologies: oxidative stress regulation, CAF modulation, and aptamer-drug conjugates. Aptabio launched health functional food Original Design Manufacturer (ODM) and pet care businesses in 2023, plans to merge Objectivo in 2025, and has successfully achieved three technology transfers with its proprietary technologies.